COMMUNIQUÉS West-GlobeNewswire

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

24/01/2025 - 22:05

Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company [...]

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24/01/2025 - 22:01

DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to six new [...]

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

24/01/2025 - 22:00

Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux

24/01/2025 - 22:00

Daix (France), New York City (New York, Etats-Unis), le 24 janvier 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites [...]

Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares following Loan Conversions

24/01/2025 - 19:30

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES FOLLOWING LOAN CONVERSIONS Conversion of EUR 0.53 million under the Sensinnovat 2020 loan, EUR 1.28 million under the 2024 convertible loan [...]

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET

24/01/2025 - 18:01

PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON TUESDAY JANUARY 28, 2025 FROM 5.30PM TO 6.45PM CET Paris, 24 January 2025, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Tuesday [...]

AB Science tiendra une conférence virtuelle le mardi 28 janvier 2025, de 17h30 à 18h45

24/01/2025 - 18:01

COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE LE MARDI 28 JANVIER 2025, DE 17H30 A 18H45 Paris, 24 janvier 2025, 18h AB Science SA (Euronext – FR0010557264 – AB) tiendra une conférence virtuelle le [...]

Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in Hepatocellular Carcinoma

24/01/2025 - 16:41

Post-hoc analysis on survival outcomes for camrelizumab plus rivoceranib in patients with viral and non-viral hepatocellular carcinoma (HCC) demonstrated clinically meaningful overall survival and progression-free [...]

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

24/01/2025 - 15:15

GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]

Privia Health to Report Fourth Quarter 2024 Results on Thursday, February 27

24/01/2025 - 15:00

ARLINGTON, Va., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth quarter and full-year periods ended December 31, [...]

Positron Corporation Secures Agreement to Sell and Rent Eight NeuSight PET-CT Scanners

24/01/2025 - 15:00

Niagara Falls, NY, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT imaging systems and [...]

Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care

24/01/2025 - 15:00

Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and cognitive change, driving innovation in brain health Company highlights its [...]

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

24/01/2025 - 14:45

THE WOODLANDS, TX, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how [...]

Cannabix and AlcoPro Enter MOU for Marijuana Breathalyzer Marketing

24/01/2025 - 14:45

VANCOUVER, British Columbia, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]

SoftSmile and ClearCorrect Announce Settlement

24/01/2025 - 14:28

NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- SoftSmile, Inc., ClearCorrect Operating, LLC, and Institut Straumann AG announce that they have amicably settled all litigation and legal disputes between them. The companies [...]

475,000 members and counting: HOOPP adds 33 new employers in 2024

24/01/2025 - 14:00

HOOPP continues to expand retirement security to more Ontario healthcare workers TORONTO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- For 65 years, HOOPP has been committed to providing members with the lifetime pension they have [...]

Gelteq Appoints Matthew Jones as Head of Sports Performance

24/01/2025 - 14:00

Leading internationally-experienced sports nutritionist joins the Company’s growing team to expand its sports vertical NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company [...]

Sword Health Acquires Surgery Hero to Accelerate Global Growth and Expand its Presence in the UK

24/01/2025 - 13:46

As part of this acquisition, Sword Health will collaborate with 18 NHS trusts serving 10 million people to implement its AI Care model, enhancing care delivery and management while significantly reducing costs LONDON [...]

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

24/01/2025 - 13:36

Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan. 24, 2025 (GLOBE NEWSWIRE [...]